During this seminar you will also hear an FDA insider’s views regarding issues facing the industry and top appellate attorneys’ thoughts regarding recent and relevant decisions affecting how we defend our clients. These and other top-notch programs make this seminar the “go-to” event year after year for practitioners in the pharmaceutical and medical device defense arena. Register today!
|Drug and Medical Device Litigation Seminar - Members||May 16, 2019 - May 17, 2019||
|Drug and Medical Device Litigation Seminar - Non-Members||May 16, 2019 - May 17, 2019||
Epidemiology is the study of the causes and patterns of diseases in populations. This science is essential to establishing general causation, that is, whether exposure to an agent is capable of causing a health effect. This webinar will provide an overview of epidemiology and explain how an exposure and a health outcome may be associated due to a causal effect or due to other, non-causal reasons. Examples will be given to illustrate how epidemiologists evaluate the weight of scientific evidence to determine whether general causation has been established.
The past 10 years have brought significant advances in the field of reliable walkway slip analysis. At the same time, the inertia of decades of questionable analysis methods has not been overcome. Many “experts” still rely upon these questionable methods. This presentation, which features numerous case studies, takes an in-depth look at methodologies, research, standards, and practical applications of tribometer testing. A brief review of litigation considerations will be discussed as well.
Federal preemption is a key defense in drug and medical device product liability cases, and the FDA’s regulatory framework is the ever-present background factor for our clients and for litigation involving their products. This webinar will provide a brief introduction to federal preemption, aimed at newer lawyers, before shifting to a robust discussion of strategically raising preemption defenses, and will conclude with a forecast of where federal preemption is headed, particularly given the impending changes to the FDA’s 510(k) clearance program.
|Preemption in Drug and Medical Device Cases: An Overview and Hot Topics - Members||Jun 20, 2019||
|Preemption in Drug and Medical Device Cases: An Overview and Hot Topics - Non-Members||Jun 20, 2019||
Minimize loss and maximize profit by employing best practices in planning for desired transition out of practice, as well as interruptions in practice like natural disasters, medical emergencies, or death.
|The Future Isn't Always Bright – Planning for the Unexpected and the Expected - Members||Jun 25, 2019||